SAB Biotherapeutics, Inc. (SABS) Investor Relations Documents

SAB Biotherapeutics, Inc. (SABS) investor relations documents from the company's IR site: 1 presentation, 21 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

SAB Corporate Presentation: SAB Biotherapeutics is developing SAB-142, a disease-modifying human anti-thymocyte globulin (hATG) currently in a Phase 2b trial for Stage 3 Type 1 Diabetes.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06PresentationSAB Corporate Presentation
2026-08-06Press releaseSAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
2026-07-30Press releaseSAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
2026-07-07Press releaseBreakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
2026-05-29Press releaseSAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual
2026-05-12Press releaseSAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
2026-05-05Press releaseSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
2026-04-22Press releaseSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established
2026-04-15Press releaseSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society C
2026-03-19Press releaseSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-03-17Press releaseSAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-03-10Press releaseSAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
2026-03-02Press releaseSAB BIO to Participate in Upcoming Investor Conferences
2026-02-04Press releaseSAB BIO to Participate in Upcoming Investor Conferences
2026-01-06Press releaseSAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseSAB Biotherapeutics to Present at Upcoming March Investor Conferences
Press releaseSAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
Press releaseSAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
Press releaseSAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
Press releaseSAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatm
Press releaseSAB Biotherapeutics Announces Research Collaboration With CSL Behring
Press releaseSAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

SABS overview · SABS earnings · SABS financials · SABS KPIs · SABS ownership · SABS peers · SABS filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.